Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR) signed a development services agreement with Indomo to manufacture engineering and clinical batches of DT-001, a corticosteroid formulation intended for use with Indomo’s ClearPen™ intradermal self-injection device. Lifecore will supply batches to support planned studies and prepare DT-001 for anticipated Phase 2 clinical trials in 2026.
The agreement expands Lifecore’s work beyond ophthalmics into device-enabled injectable therapeutics and continues a prior collaboration on formulation and process optimization for DT-001.
Positive
- Lifecore to produce engineering and clinical batches for DT-001
- Program advancing toward anticipated Phase 2 clinical trials in 2026
- Expanded CDMO scope beyond ophthalmic therapies into autoinjector technologies
Negative
- DT-001 still pre-Phase 2, commercial outcomes remain uncertain
- Current corticosteroid injection adoption is low: 1M patients receive injections versus 50M affected
News Market Reaction – LFCR
In the Mar 5 session, LFCR declined 0.57%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Conference participation | Neutral | +1.1% | Announced participation at DCAT Week 2026 for customer and partner meetings. |
| Jan 16 | Equity inducement grants | Neutral | +0.4% | Reported RSU and option grants to newly hired employees under inducement plan. |
| Dec 18 | Index inclusion | Positive | -0.6% | Planned addition to the Nasdaq Biotechnology Index following annual reconstitution. |
| Dec 17 | CDMO master agreement | Positive | +9.9% | Signed CDMO master services deal with large multinational pharma for injectable product. |
| Dec 16 | Conference participation | Neutral | -2.2% | Announced participation in the 44th Annual J.P. Morgan Healthcare Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive commercial/partnership news has often aligned with gains, while index/conference items show mixed reactions.
Over the past several months, Lifecore has issued a series of strategic and corporate updates. A Dec 17, 2025 CDMO master services agreement with a large multinational customer coincided with a 9.86% gain, highlighting market focus on contract wins. Inclusion in the Nasdaq Biotech Index on Dec 18, 2025 saw a modest -0.59% move, and conference participation headlines in December 2025 and February 2026 produced small, mixed reactions. The new Indomo agreement extends this CDMO-focused trajectory, adding another development services relationship to the company’s growing pipeline of injectable programs.
Key Terms
intradermal medical
self-injection device technical
cdmo financial
corticosteroid medical
triamcinolone acetonide medical
microneedle medical
intralesional injections medical
phase 2 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen™, its Proprietary Intradermal Self-Injection Device
Lifecore to Manufacture Drug Batches in Preparation for Planned Clinical Trials
CHASKA, Minn. and BOSTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), and Indomo, a clinical-stage company dedicated to expanding access to quality healthcare via innovative device-enabled therapeutics, today announced that the companies have entered into a new development services agreement through which Lifecore will provide Indomo with a range of CDMO services to support the continued development of its corticosteroid drug candidate, DT-001. Indomo is developing DT-001 to be combined with its investigational intradermal self-injection device, the ClearPen™, as a treatment for inflammatory acne lesions.
This represents the second agreement signed by the companies, with Lifecore having previously been selected to provide formulation and process optimization activities in support of the DT-001 program. Under the terms of the latest agreement, Lifecore will be responsible for producing and supplying engineering and clinical batches of DT-001 to Indomo for planned studies designed to prepare the product for anticipated advancement into Phase 2 clinical trials in 2026.
“We are thrilled to continue to grow our relationship with Indomo and support a customer that possesses such high-quality leadership and ambitious plans for innovation. This work with Indomo highlights the success of our continued efforts to expand beyond our traditional focus in ophthalmic therapies, while also enhancing our leadership in rapidly growing autoinjector technologies,” said Paul Josephs, president and chief executive officer of Lifecore. “We are excited to get to work on producing engineering and clinical batches for Indomo and supporting the company’s plans to move into Phase 2 studies.”
Built by a team with deep expertise in medical devices, consumer health, and skincare, Indomo’s investigational ClearPen system pairs a proprietary self-injection device and microneedle with a modernized formulation of triamcinolone acetonide to enable consistent dosing for at-home administration.
Intralesional injections of triamcinolone acetonide, a corticosteroid backed by more than 50 years of clinical use and a strong safety profile, are recommended as one of the first-line treatments for acne by the American Academy of Dermatology. Acne is the most common skin condition in the U.S., affecting 50 million Americans annually, yet only one million people are regularly receiving corticosteroid injections to treat their inflammatory lesions. The root cause of this issue is accessibility. With only 12,000 dermatologists in the U.S., there is only one dermatologist for every 28,000 Americans. Indomo aims to improve access by pursuing an at-home approach intended to empower patients with timely access to care.
“As we progress toward Phase 2 studies, it was critical for Indomo to partner with a CDMO that combines technical excellence with a forward-looking approach to innovation. Lifecore’s expanding leadership in injectable therapeutics and their commitment to speed and high-quality execution position them as a key partner in advancing our therapeutic pipeline. We are excited to deepen this collaboration as we move into the next phase of development,” said Rick Bente, chief executive officer of Indomo.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
About Indomo
Indomo is reimagining clinical dermatology with trusted science and precision technology, bringing medical-grade care into the home. A clinical-stage therapeutics company, Indomo pairs proven medicines with novel delivery systems to create fast-acting, self-administered treatments for inflammatory skin conditions. Its debut product, the ClearPen, will combine an established, trusted therapeutic with a novel microneedle device for at-home acne treatment. Indomo is backed by leading investors including Atomic, Foresite Capital, and Polaris Partners. Founded by leaders from Hims & Hers, Medtronic, and Starface, Indomo brings together deep expertise in telehealth, medical devices, and consumer skincare. To learn more about Indomo and their Phase 2 clinical trials, head here.
Disclaimer: The Indomo ClearPen has not yet been approved or cleared by the U.S. Food and Drug Administration and is considered investigational; preparations are underway for Phase 2 clinical trials.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding future events and Lifecore’s future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. In addition, all statements regarding Lifecore’s expansion of Lifecore’s CDMO business, broadening of Lifecore’s commercial customer base, the anticipated advancement of Indomo’s DT-001 program into Phase 2 clinical trials in 2026, our efforts to expand beyond Lifecore’s traditional focus in ophthalmic therapies, enhancing Lifecore’s leadership in rapidly growing autoinjector technologies, Lifecore’s forward-looking approach to innovation, Lifecore’s expanding leadership in injectable therapeutics, and Lifecore’s commitment to speed and high-quality execution are forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, the timing and amount of future expenses, revenue, net income (loss), Adjusted EBITDA, cash flow and capital requirements, and timing and availability of and the need for additional financing; Lifecore’s ability to maintain or expand Lifecore’s relationships with Lifecore’s current customers, including the impact of changes in consumer demand for the products Lifecore manufactures for Lifecore’s customers; Lifecore’s ability to grow and diversify Lifecore’s business with new customers, including the potential loss of development customers or delays in our development customers’ programs if they do not receive required funding or regulatory approvals, or for other reasons; Lifecore’s ability to comply with covenants under Lifecore’s credit agreements and to pay required interest and principal payments when due; Lifecore’s ability to fund any redemptions of shares of its outstanding Series A Convertible Preferred Stock if requested by holders in accordance with their terms; Lifecore’s ability to raise additional capital for ongoing needs, including through equity financing, debt financing, collaborations, strategic alliances or licensing arrangements; the impact of macroeconomic events or circumstances on Lifecore’s operations and financial performance, including inflation, tariffs, interest rates, social unrest and global instability; the performance of Lifecore’s third-party suppliers; pharmaceutical industry market forces that may impact Lifecore’s customers’ success and continued demand for the products Lifecore produces for those customers; Lifecore’s ability to recruit or retain key scientific, technical, business development, and management personnel and Lifecore’s executive officers; Lifecore’s ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including current Good Manufacturing Practice, or cGMP; the outcome and cost of existing and any new litigation or regulatory proceedings; and other risk factors set forth from time to time in the company’s filings with the Securities and Exchange Commission (“SEC”), including, but not limited to, the Annual Report on Form 10-K for the year ended May 25, 2025 (the “2025 10-K”). For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to Lifecore’s filings with the SEC, including the risk factors contained in the 2025 10-K. Forward-looking statements represent management’s current expectations as of the date hereof and are inherently uncertain. Except as required by law, Lifecore does not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.
Lifecore Biomedical, Inc. Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors & Media)
415-675-7401
sdiaz@vidasp.com
Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
ryan.lake@lifecore.com
